On July 17, 2026, the results of the eighth China Best Managed Companies (BMC) project, jointly organized by Deloitte China, the Hong Kong University of Science and Technology Business School, and the Harvard Business Review Chinese edition, were announced. Fosun Pharma has been named to the "China Best Managed Companies" list for the fourth consecutive year, once again demonstrating the company's comprehensive management strength in strategic foresight, innovation execution, global governance, and financial health. The BMC project is China's only international award that provides a comprehensive assessment of corporate management systems, renowned globally for 33 years with a network spanning nearly 50 countries and regions worldwide.
This year's selection process involved six months of confidential recommendations, interviews with entrepreneurs, and expert research. It was based on the global "Deloitte BMC Excellence Management Standard" framework and conducted a comprehensive evaluation across four areas—corporate strategy, capabilities, commitment, and financial strength—through the "CXO Excellence Management Lab." As a global pharmaceutical and health industry group rooted in China and driven by innovation, Fosun Pharma actively implements its core strategy of "innovation-led growth, deep internationalization, and fully embracing AI." With innovation and globalization as its dual engines, the company achieved operating revenue of RMB 41.662 billion in 2025. Of this, revenue from innovative drugs reached RMB 9.893 billion, a year-on-year increase of 29.59%, accounting for 33.16% of its pharmaceutical business revenue. Revenue from overseas markets amounted to RMB 12.977 billion, a year-on-year increase of 14.87%, representing 31.15% of total revenue. The quality and efficiency of operations continue to improve, underpinning stable, high-quality development.
In the field of innovation, Fosun Pharma continues to strengthen its pipeline development focused on three core areas: oncology, immunology/inflammation, and neurodegenerative diseases. Through diversified innovation models including in-house R&D, collaborative development, and in-licensing, the company continuously solidifies its core technology platforms such as antibodies and ADCs, small molecules, and cell therapy. It is also actively expanding into cutting-edge technological directions like radiopharmaceuticals and small nucleic acids, enhancing early-stage innovation capabilities and accelerating the translation of scientific research achievements. In 2025, Fosun Pharma's total R&D investment reached RMB 5.913 billion, of which R&D investment related to innovative drugs amounted to RMB 4.303 billion, a year-on-year increase of 15.98%, accounting for 80.26% of its pharmaceutical R&D expenditure.
During 2025, a total of 7 innovative drugs from Fosun Pharma, covering 16 indications, received marketing approvals in China and overseas. Marketing applications for 6 innovative drug varieties were accepted, and nearly 40 innovative drug clinical trials received approvals from regulatory authorities in China, the United States, and Europe. Regarding its global layout, Fosun Pharma continues to deepen its internationalization across multiple dimensions including innovative R&D, production quality, registration, commercialization, and academic influence. It has established a global operational network covering markets in China, the United States, Europe, Africa, India, and Southeast Asia, with a global commercial team exceeding 6,000 people. The company's international development model is continuously evolving from "product export" to "system export."
Fosun Pharma already has 17 manufacturing workshops/production lines in China that have obtained GMP certifications from major regulatory markets such as the US, the EU, and the WHO. Its biologics production lines have achieved regular supply to markets including China, Europe, Latin America, Southeast Asia, and India. In the realm of AI and digital intelligence, Fosun Pharma places high importance on the transformative potential of AI technology in the pharmaceutical and health sectors. It systematically promotes the platformization, engineering, and large-scale implementation of AI capabilities across core processes such as new drug R&D, clinical research, product services, and operational management.
Using the "PharmAID Medical Intelligence Platform" as its core digital intelligence foundation and relying on the "AquaVista Data Integration Platform" to continuously strengthen its data infrastructure, the company is focusing on developing innovative application scenarios like the "MedAlkaid Research Intelligence Agent." These initiatives have achieved large-scale implementation in areas including target discovery, molecular optimization, clinical decision-making, project evaluation, and process efficiency, allowing Fosun Pharma to take a leading position in building a new competitive advantage in "AI + Pharmaceuticals." The company's fourth consecutive year of recognition by the BMC authority validates its management system and strategic execution capabilities. Looking ahead, the company will continue to focus on unmet clinical needs, accelerate the R&D and translation of globally leading technologies and innovative products, and strive to become a first-class enterprise in the global healthcare market, contributing to the high-quality development of China's pharmaceutical industry.
Comments